---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-22-304456"
form_type: "8-K"
ticker: "KYMR"
cik: "0001815442"
company_name: "Kymera Therapeutics, Inc."
filed_at: "2022-12-14T23:59:59+00:00"
generated_at: "2026-06-21T04:51:41.526157+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "medium"
source: SEC EDGAR
---

# Kymera provides clinical update on KT-474 Phase 1 Part C in HS & AD; oncology pipeline update

## Summary
- Held virtual investor event to present Part C Phase 1 data for KT-474 (IRAK4 degrader) in hidradenitis suppurativa and atopic dermatitis.
- Also discussed updates on the company's oncology pipeline programs.
- Full presentation furnished as Exhibit 99.1; no specific numerical results disclosed in the filing text.

## SEC filing metadata
- accession: 0001193125-22-304456
- form_type: 8-K
- ticker: KYMR
- cik: 0001815442
- company_name: Kymera Therapeutics, Inc.
- filed_at: 2022-12-14T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: medium
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1815442/000119312522304456/0001193125-22-304456-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1815442/000119312522304456/d313389d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-22-304456
- JSON: https://secwatch.observer/filing/0001193125-22-304456.json
- Plain text: https://secwatch.observer/filing/0001193125-22-304456.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.